New antibody drug aims to shrink advanced tumors in early trial

NCT ID NCT07223125

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-phase study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The drug is designed to deliver a toxic payload directly to cancer cells. The main goals are to find a safe dose and check for side effects. Around 360 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED-STAGE SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial endometrioid adenocarcinoma lung adenocarcinoma nonpapillary renal cell carcinoma ovarian endometrioid adenocarcinoma papillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED-STAGE SOLID TUMORS

Contacts and locations

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32803, United States
Centre Leon Berard
RECRUITING

Lyon, 69373, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
NEXT Oncology
RECRUITING

Irving, Texas, 75039, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Severance Hospital Yonsei University Health System
RECRUITING

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.